Literature DB >> 12210808

Bcl-2 family of proteins in indolent B-cell non-Hodgkin's lymphoma: study of 116 cases.

Beamon Agarwal1, Kikkeri N Naresh.   

Abstract

The bcl-2 family of proteins comprises both antagonists and agonists of apoptosis. We have investigated whether subsets of indolent B-cell non-Hodgkin's lymphoma (IB-NHL) differ in the expression of the bcl-2 family members; 116 cases of IB-NHL, composed of chronic lymphocytic leukemia (CLL, n = 48), follicular lymphoma (FL, n = 38), marginal zone B-cell lymphoma (MZBCL, n = 15), and mantle cell lymphoma (MCL, n = 15), were investigated for expression of bcl-2, bcl-X, mcl-1, bax, and bak proteins by immunohistochemistry. Expression of bcl-2 and bcl-X proteins was moderate/high among most IB-NHLs. Expression of mcl-1 was low/absent in most cases of CLL and MCL and low/moderate in most cases of FL and MZBCL. Most MCLs did not express bax protein. Bax expression was absent/low among most cases of CLL and low/moderate among most cases of FL and MZBCL. Expression of bak was moderate/low among most cases of CLL, MZBCL, and MCL but was absent/low among most cases of FL. The different subsets of IB-NHLs differ in their expression of mcl-1, bax, and bak proteins. Copyright 2002 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12210808     DOI: 10.1002/ajh.10139

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  15 in total

Review 1.  The role of aberrant proteolysis in lymphomagenesis.

Authors:  Anagh A Sahasrabuddhe; Kojo S J Elenitoba-Johnson
Journal:  Curr Opin Hematol       Date:  2015-07       Impact factor: 3.284

2.  Immunophenotypic Characterization of Canine Splenic Follicular-Derived B-Cell Lymphoma.

Authors:  Leah Stein; Cynthia Bacmeister; Kris Ylaya; Patricia Fetsch; Zengfeng Wang; Stephen M Hewitt; Matti Kiupel
Journal:  Vet Pathol       Date:  2019-01-13       Impact factor: 2.221

Review 3.  Survival control of malignant lymphocytes by anti-apoptotic MCL-1.

Authors:  Y Fernández-Marrero; S Spinner; T Kaufmann; P J Jost
Journal:  Leukemia       Date:  2016-08-01       Impact factor: 11.528

4.  Curcumin nanodisk-induced apoptosis in mantle cell lymphoma.

Authors:  Amareshwar T K Singh; Mistuni Ghosh; Trudy M Forte; Robert O Ryan; Leo I Gordon
Journal:  Leuk Lymphoma       Date:  2011-06-24

5.  Bcl-2 Is a Therapeutic Target for Hypodiploid B-Lineage Acute Lymphoblastic Leukemia.

Authors:  Ernesto Diaz-Flores; Evan Q Comeaux; Kailyn L Kim; Ella Melnik; Kyle Beckman; Kara L Davis; Kevin Wu; Jon Akutagawa; Olga Bridges; Roberta Marino; Margo Wohlfeil; Benjamin S Braun; Charles G Mullighan; Mignon L Loh
Journal:  Cancer Res       Date:  2019-03-12       Impact factor: 12.701

Review 6.  Novel Treatments for Pediatric Relapsed or Refractory Acute B-Cell Lineage Lymphoblastic Leukemia: Precision Medicine Era.

Authors:  Shang Mengxuan; Zhou Fen; Jin Runming
Journal:  Front Pediatr       Date:  2022-06-23       Impact factor: 3.569

7.  Non-Hodgkin and Hodgkin Lymphomas Select for Overexpression of BCLW.

Authors:  Clare M Adams; Ramkrishna Mitra; Jerald Z Gong; Christine M Eischen
Journal:  Clin Cancer Res       Date:  2017-08-29       Impact factor: 12.531

8.  Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia.

Authors:  Susan M O'Brien; David F Claxton; Michael Crump; Stefan Faderl; Thomas Kipps; Michael J Keating; Jean Viallet; Bruce D Cheson
Journal:  Blood       Date:  2008-10-17       Impact factor: 22.113

9.  Safety and efficacy of navitoclax, a BCL-2 and BCL-XL inhibitor, in patients with relapsed or refractory lymphoid malignancies: results from a phase 2a study.

Authors:  Sven de Vos; John P Leonard; Jonathan W Friedberg; Jasmine Zain; Kieron Dunleavy; Rod Humerickhouse; John Hayslip; John Pesko; Wyndham H Wilson
Journal:  Leuk Lymphoma       Date:  2020-11-25

Review 10.  Targeting the mitochondrial apoptotic pathway: a preferred approach in hematologic malignancies?

Authors:  K Brinkmann; H Kashkar
Journal:  Cell Death Dis       Date:  2014-03-06       Impact factor: 8.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.